Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 23NIH 2UNKNOWN 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Head and Neck Neoplasms 5Stomatitis 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mucositis 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × Radiotherapy, Intensity-Modulated × Clear all
NCT03840902 2024-01-16

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

EMD Serono

Phase 2 Terminated
153 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡